These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19446719)

  • 41. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting CCR5 for anti-HIV research.
    Gu WG; Chen XQ
    Eur J Clin Microbiol Infect Dis; 2014 Nov; 33(11):1881-7. PubMed ID: 25027072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc.
    Wheeler J; McHale M; Jackson V; Penny M
    Antivir Ther; 2007; 12(2):233-45. PubMed ID: 17503665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.
    Wood A; Armour D
    Prog Med Chem; 2005; 43():239-71. PubMed ID: 15850827
    [No Abstract]   [Full Text] [Related]  

  • 46. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance.
    Karash A; Mazzoni MR; Gilchrist A
    Curr Top Med Chem; 2014; 14(13):1553-73. PubMed ID: 25159162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CCR5 inhibitors in HIV-1 therapy.
    Dorr P; Perros M
    Expert Opin Drug Discov; 2008 Nov; 3(11):1345-61. PubMed ID: 23496169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biology of CCR5 and its role in HIV infection and treatment.
    Lederman MM; Penn-Nicholson A; Cho M; Mosier D
    JAMA; 2006 Aug; 296(7):815-26. PubMed ID: 16905787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA panel backs HIV drug.
    AIDS Read; 2007 Jun; 17(6):294. PubMed ID: 17632933
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
    Martin-Blondel G; Bauer J; Uro-Coste E; Biotti D; Averseng-Peaureaux D; Fabre N; Dumas H; Bonneville F; Lassmann H; Marchou B; Liblau RS; Brassat D
    Acta Neuropathol; 2015 Mar; 129(3):463-5. PubMed ID: 25589222
    [No Abstract]   [Full Text] [Related]  

  • 52. Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type 5.
    Speck-Planche A; Cordeiro MN
    Curr Comput Aided Drug Des; 2011 Dec; 7(4):238-48. PubMed ID: 22050678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.
    Martin-Blondel G; Brassat D; Bauer J; Lassmann H; Liblau RS
    Nat Rev Neurol; 2016 Feb; 12(2):95-105. PubMed ID: 26782333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monoclonal CCR5 Antibody: A Promising Therapy for HIV.
    Zhao L; Lai Y
    Curr HIV Res; 2023; 21(2):91-98. PubMed ID: 36927434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.
    Knepp AM; Grunbeck A; Banerjee S; Sakmar TP; Huber T
    Biochemistry; 2011 Feb; 50(4):502-11. PubMed ID: 21155586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.
    Jiao X; Nawab O; Patel T; Kossenkov AV; Halama N; Jaeger D; Pestell RG
    Cancer Res; 2019 Oct; 79(19):4801-4807. PubMed ID: 31292161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The G protein coupled receptor CCR5 in cancer.
    Upadhyaya C; Jiao X; Ashton A; Patel K; Kossenkov AV; Pestell RG
    Adv Cancer Res; 2020; 145():29-47. PubMed ID: 32089164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CCR5: From Natural Resistance to a New Anti-HIV Strategy.
    Lopalco L
    Viruses; 2010 Feb; 2(2):574-600. PubMed ID: 21994649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How pharmacological receptor theory can guide new drug discovery CCR5 HIV inhibitors in AIDS as a case study.
    Kenakin T
    Proc West Pharmacol Soc; 2007; 50():1-7. PubMed ID: 18605221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plan launched to find HIV cure.
    Corbyn Z
    Lancet; 2012 Jul; 380(9838):203-4. PubMed ID: 22826833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.